Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

NCT03942315 | Completed

• 1 other identifier: HHT
• Study Type: observational
• Target: 14
• Locations: 0 countries
• Sites: N/A

Brief Summary

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.

Conditions

Hereditary Haemorrhagic Telangiectasia; Liver Transplant

Outcome Measures

Primary Outcomes (1)

• Change in graft status after liver transplant for Hereditary Haemorrhagic Telangiectasia (HHT) (risk of recurrence)

  Recurrent clinical examinations (including laboratory, histological and radiological investigations)

  Every 6 months after transplantation up to 5 years

Study Arms (1)

Liver transplant in Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.

Other: Data collection from standard follow-up after liver transplant

Interventions

Data collection from standard follow-up after liver transplant OTHER

All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.

Liver transplant in Hereditary Hemorrhagic Telangiectasia

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hereditary Hemorrhagic Telangiectasia (HHT) patient who underwent liver transplant

You may qualify if:

• Hereditary Hemorrhagic Telangiectasia (HHT) patient who underwent liver transplant for HHT

You may not qualify if:

• Patient who died in the year following transplantation

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

MeSH Terms

Conditions

Telangiectasia, Hereditary Hemorrhagic

Condition Hierarchy (Ancestors)

Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Telangiectasis; Hemorrhagic Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Vascular Malformations; Cardiovascular Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Jérôme DUMORTIER, MD

  Hospices Civils de Lyon (Hôpital Edouard Herriot )

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2019
• First Posted: May 8, 2019
• Study Start: January 1, 2011
• Primary Completion: February 1, 2018
• Study Completion: December 1, 2018
• Last Updated: May 8, 2019

Record last verified: 2019-05